A Brave New World for Biosimilars: How labeling requirements may impact preemption of product liability claims
Genetic Engineering & Biotechnology News (2015)

Are IPRs Impacting the Pharmaceutical Industry? (2015)

Clinical Trials, Social Media, and Your Patent
Applied Clinical Trials (2016)

Distributing patent rights between affiliates: guidelines to support enforcement rights around the world
DLA Piper Intellectual Property and Technology News (2015)

Biosimilars in the US: It’s all shook up
Genetic Engineering & Biotechnology News (2015)

The FTC Gets Activist Post-Activis
Genetic Engineering & Biotechnology News  (2015)

Substitution Allowed? State Biosimilar Laws Are Evolving
Genetic Engineering & Biotechnology News  (2015)

Take a Little Off the Top: Patent Bills Target Hedge Funds
IP Pro Life Sciences  (2015)

Is the Government Hopping Over the Line with Its Product-hopping Stance?
Intellectual Property Magazine  (2015)

Will Post-Grant Reviews Find a Place in the Molecular Diagnostic Industry?
Bloomberg BNA Life Sciences Law and Industry Report  (2015)

Factors to Consider Before Making Any Patent Moves in Japan
Law360  (2016)

Where Do We Go From Here? The Evolving Landscape of Molecular Diagnostics
Bloomberg BNA Life Sciences Law and Industry Report  (2016)

Don’t Overlook Evidentiary Issues in Post-Grant Proceedings
Law360  (2016)

Machine learning: new discoveries and challenges for life sciences
Life Sciences IP Review (2017)

Is Antitrust Law Best Way to Deal With Pharma Costs?
Intellectual Property Magazine  (2016)

Life Sciences Patents: Method Claims—United They Stand, Divided Do They Fall?
Bloomberg Law Insights  (2016)

No attorney-client relationship is created between INGENSITY™ IP and visitors to INGENSITY™ IP’s website.  The content of this website is for informational purposes only and does not offer legal advice. Circumstances are fact-specific and you should consult an attorney for legal advice concerning your individual issues.